Hormones · Melatonin

Melatonin and melatonin receptor agonists reduce delirium risk in hospitalized patients

In a network meta-analysis of 33 randomized controlled trials involving 5045 patients, melatonin and melatonin receptor agonists were associated with a 23% lower risk of delirium compared with non-active control conditions (RR=0.77, 95% CI: 0.64-0.92). The effect was more evident in non-ICU and surgical populations, but the certainty of evidence was low to moderate.

1 min read•Updated Sep 2, 2026•0 RCTs•1 Meta-analyses•View structured evidence →
Evidence Score49/100
Human RCT☆☆☆☆☆
Meta-analysis★★★☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.

Melatonin and melatonin receptor agonists reduce delirium risk in hospitalized patients The current body of evidence comprises 1 study and 1 meta-analysis. EvidenceHub rates the overall confidence at 49/100 (low).

The Claim

Melatonin and melatonin receptor agonists reduce delirium risk in hospitalized patients

This conclusion is most relevant to: Hospitalized patients (including non-ICU and surgical populations) at risk for delirium.

What the Research Shows

The conclusion draws on 1 linked study. Highlights from the cited literature:

  • ▸Sleep-modulating pharmacological interventions for delirium prevention: a systematic review and a network meta-analysis of randomized controlled trials. (Sleep medicine reviews, 2026) —

How It Works

The proposed biological pathway:

  • ▸Melatonin agonists bind to melatonin receptors in the suprachiasmatic nucleus
  • ▸This regulates circadian rhythms and promotes sleep
  • ▸Improved sleep and circadian alignment may reduce neuroinflammation and delirium triggers
  • ▸Result: Lower incidence of delirium

Who Might Benefit

Evidence fit by population:

  • ▸Hospitalized patients (including non-ICU and surgical populations) at risk for delirium

Limitations & Caveats

Important context when interpreting this evidence:

  • ▸Certainty of evidence ranged from low to moderate
  • ▸Limited direct comparisons between active interventions
  • ▸Agent-specific evidence base; findings may not generalize to all melatonin receptor agonists

Frequently Asked Questions

What is the effect of melatonin on delirium prevention?▼

Melatonin and melatonin receptor agonists reduce delirium risk by 23% compared to control (RR=0.77, 95% CI: 0.64-0.92).

In which patient populations is melatonin most effective for delirium prevention?▼

Subgroup analyses suggest the effect is more evident in non-ICU and surgical populations.

How does melatonin compare to suvorexant for delirium prevention?▼

Both melatonin (RR=0.77) and suvorexant (RR=0.51) reduce delirium risk, but direct comparisons are limited.

Are benzodiazepines like midazolam effective for delirium prevention?▼

No, midazolam-based benzodiazepines did not show a statistically significant reduction in delirium risk (RR=1.64, 95% CI: 0.81-3.31).

References

  1. 1.Chen H, Zhao Y, Li Y, Chen W, Tan X. “Sleep-modulating pharmacological interventions for delirium prevention: a systematic review and a network meta-analysis of randomized controlled trials..” Sleep medicine reviews, 2026. PMID: 42673734 DOI: 10.1016/j.smrv.2026.102365
Disclaimer: This article is auto-generated from structured research data for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.